科济生物医药（上海）有限公司 Mediaroom

CARsgen® to Present Zevor-cel, CT071 and CT0590 at ASH 2024 Annual Congress

SHANGHAI, Nov. 6, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK),...

2024-11-06 21:50 1484

CARsgen® U.S. Clinical Holds Lifted by FDA

SHANGHAI, Oct. 31, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK)...

2024-11-01 09:33 1589

CARsgen® Announces 2024 Interim Results

SHANGHAI, Aug. 29, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK)...

2024-08-29 20:50 3456

CARsgen Announces Enrollment Completion in China GC/GEJ Pivotal Phase II Clinical Trial of the First-in-class Claudin18.2 CAR T (Satri-cel)

SHANGHAI, Aug. 19, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK)...

2024-08-19 20:50 2145

CARsgen Presents First-in-human Results of GPRC5D Targeting CAR-T CT071 at EHA 2024

SHANGHAI, June 15, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK)...

2024-06-15 20:50 3329

CARsgen Presents Updated Results on Satri-cel in Nature Medicine and at 2024 ASCO

SHANGHAI, June 4, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK),...

2024-06-04 20:50 1671

CARsgen Submitted Responses to FDA Observations

SHANGHAI, April 29, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK...

2024-04-29 20:50 1177

CARsgen Announced 2023 Annual Results

SHANGHAI, March 27, 2024 /PRNewswire/ -- March 27, 2024, CARsgen Therapeutics Holdings Limited (Sto...

2024-03-27 20:50 2361

NMPA Approves the NDA for CARsgen's BCMA CAR-T Therapy Zevorcabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma

SHANGHAI, March 1, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK)...

2024-03-01 21:50 2087

CARsgen's Presents Updated Research Results on CT041 at 2024 ASCO GI Meeting

SHANGHAI, Jan. 19, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK)...

2024-01-19 21:50 1906

CARsgen's CT011 achieves IND clearance from the NMPA for the GPC3-positive stage Ⅲa hepatocellular carcinoma at high risk of recurrence after surgical resection

SHANGHAI, Jan. 15, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK)...

2024-01-15 21:50 1852

CARsgen Presents Updated Research Results on Zevor-cel at 2023 ASH Annual Meeting

SHANGHAI, Dec. 12, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK)...

2023-12-12 21:50 1648

CARsgen's CT071 Received IND Clearance from the FDA for Treating Relapsed/Refractory Multiple Myeloma or Relapsed/Refractory Primary Plasma Cell Leukemia

SHANGHAI, Dec. 4, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK),...

2023-12-04 21:50 1401

CARsgen Announces Formation of its Clinical Advisory Board

SHANGHAI, Nov. 20, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK)...

2023-11-20 21:50 2723

CARsgen Announces Formation of its Clinical Advisory Board

CARsgen's CAR-GPC3 T-cell Therapy for Advanced Hepatocellular Carcinoma: Two Patients Achieved over 7 Years of Disease-free Survival

SHANGHAI, Oct. 12, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK)...

2023-10-12 20:50 1731

CARsgen's CAR-GPC3 T-cell Therapy for Advanced Hepatocellular Carcinoma: Two Patients Achieved over 7 Years of Disease-free Survival

Two Cases of Pancreatic Cancer Treatment with CARsgen's CT041 Published in Journal of Hematology & Oncology

SHANGHAI, Sept. 21, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK...

2023-09-21 16:00 1492

CARsgen Announced 2023 Interim Results

SHANGHAI, Aug. 22, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK)...

2023-08-22 19:30 3334

CARsgen Initiates Phase 2 Clinical Trial for CLDN18.2 CAR T-cell Product CT041 in the U.S.

SHANGHAI, May 18, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK),...

2023-05-18 20:50 2336

CARsgen's CLDN18.2 mAb AB011 Achieves IND Clearance from the NMPA for the First-line Combination Treatment of Gastric Cancer

SHANGHAI, May 5, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), ...

2023-05-05 20:50 3374

CARsgen's CAR T-cell Candidate CT041 Achieves IND Clearance from the NMPA for the Postoperative Adjuvant Therapy of Pancreatic Cancer

SHANGHAI, April 20, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK...

2023-04-20 20:50 2395

Latest News